Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin for OTC allergy relief

This article was originally published in The Tan Sheet

Executive Summary

Almost half (42%) of allergy-sufferers surveyed intend to purchase Schering-Plough's Claritin (loratadine) when it is available OTC, according to study by market research firm Ipsos PharmTrends. Results indicate Claritin "would displace all other OTC and Rx drugs as the preferred remedy," since current OTC category leader, Pfizer Consumer Healthcare's Benadryl, was used by about 32% of allergy sufferers interviewed. Ipsos predicts S-P's successful DTC brand awareness campaign will "carry into the OTC arena, placing incremental pressure" on competing drugs; firm found 91% of allergy sufferers have heard of Claritin. Survey involved random sample of 1,000 adults nationwide...

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Topics

UsernamePublicRestriction

Register

PS094027

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel